High-Value Federal Grants ($5M+) — December 23, 2025

Contracts totaling $42.8B for Savannah River, Argonne, Stanford, and Hanford signal entrenched revenue for Fluor subsidiary and tank ops LLC through 2026-2027.

Boeing ISS ($22.3B), SpaceX Commercial Crew ($3B), and multiple facilities ops contracts ($2.7B combined) lock in 80%+ outlays for space primes amid 33-year durations.

14 GSA awards totaling $2.6B, including Booz Allen ($2.6B potential), CACI ($1.3B), Peraton ($883M), highlight multi-year backlog in engineering/IT for defense.

UChicago Argonne ($16.7B) and Stanford ($14.5B) provide cost-reimbursement funding without fees, limiting equity upside.

2026 expirations for $65B+ (70% of total value) risk non-renewal or recompetition.

Low outlays (<20%) on $25B+ contracts (e.g., Boeing $2.4B/22B, Stanford $3.4B/14B) signal funding pacing delays.

Award fee/incentive structures in 20+ cost-plus contracts tie ~$40B to performance evaluations.

Subawards averaging 25% of value ($20B+ across 3,000+ awards) introduce subcontractor dependencies.

Unexercised options totaling $20B+ (e.g., McKesson $8.1B ceiling, Booz Allen $2.6B, CACI $1.3B) for scaling via exercises.

HHS/CMS outsourcing in health IT/claims ($1B+) and vaccine distribution positions for recurring needs post-2028.

Small/SDVOSB set-asides (e.g., Bluestag $649M, Aerodyne $531M) offer M&A targets with non-competitive upside.

$43B DOE contracts for site ops/waste treatment through 2027 underscore bipartisan funding stability.

$27B NASA awards averaging 20+ year durations signal ISS/launch continuity despite commercial shifts.

GSA dominates $3B+ in engineering/IT with 5-year potentials to 2029.

{"entity"=>"Fluor (Savannah River $25B)", "reason"=>"Largest single award (27% of total); 2026 end risks $11B options.", "trigger"=>"DOE NNSA recompete RFP or extension notice"}

{"entity"=>"Boeing (ISS $22B)", "reason"=>"Ultra-long 33-year contract with low 11% outlay flags pacing.", "trigger"=>"Outlay acceleration >$500M/quarter or NASA budget cuts"}

{"entity"=>"McKesson (CDC Vaccine $8.1B ceiling)", "reason"=>"Massive option upside from $153M obligation in recurring distribution.", "trigger"=>"Option exercise >$1B or HHS pandemic preparedness funding"}

{"entity"=>"2026-Expiring DOE/NASA Portfolio ($65B)", "reason"=>"Cluster of mega-contracts ending Sep 2026 demands renewal tracking.", "trigger"=>"Protest filings or new awards to competitors"}